WEKO3
アイテム
{"_buckets": {"deposit": "2fa87017-3648-47ed-87ab-6ac1e0c60fdb"}, "_deposit": {"created_by": 1, "id": "68309", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "68309"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00068309", "sets": ["28"]}, "author_link": ["670615", "670619", "670622", "670626", "670621", "670623", "670617", "670624", "670627", "670618", "670614", "670620", "670612", "670625", "670616", "670613"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2006-01-28", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Introduction: \nWe reported that the 4-fraction/1-week carbon ion radiotherapy (CIRT) appeared to be safe and to have a promising potential as a new, radical, and minimally invasive therapeutic option for hepatocellular carcinoma (HCC) at the 2004 ASCO annual meeting. In order to evaluate the safety and efficacy of 2-fraction/2-day CIRT, the next clinical trial was conducted within a phase I/II study between April 2003 and August 2005.\nMethods:\nThe subjects of this report were 32 patients with follow-up period of over 6 months. CIRT was administered in doses of 32.0 to 38.8 cobalt gray equivalent (GyE) in 2 fractions for 2 days in a step-wise dose-escalation study. The median age was 68 (53-80) years. All patients had chronic liver diseases of Child-Pugh grade A in 30 or B in 2. Nine patients had intrahepatic recurrent lesions. The median tumor size was 4.7 (2.0-6.0) cm in diameter. Because no evaluation criteria are available for general hepatic toxicity in the impaired liver, the General Hepatic Toxicity Criteria based on NCI-CTC was defined by the Liver Cancer Working Group.\nResults: \nDuring a median follow-up of 18 (6-28) months, no treatment-related death occurred. Grade 3 hepatic toxicity according to NCI-CTC was observed in one patient in serum-GOT, GPT, T.BIL, and prothrombin activity. Grade 3 general hepatic toxicity occurred in the same one. No other Grade 3 or worse adverse events have occurred. The overall tumor response rate was 91% (29/32) at 6 months after the therapy. One-year and 1.5-year local control rate was 96% (23/24) and 88% (15/17), respectively. One-year and 1.5-year overall survival rate was 100% (24/24) and 94% (17/18), respectively. There were preliminarily no differences in results between the 2-fraction and 4-fraction CIRT.\nConclusion:\nTwo-fraction CIRT for HCC appears preliminarily safe and effective as well as the 4-fraction one. However, further observation is needed because the follow-up period is too short to confirm its clinical efficacy.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "2006 Gastrointestinal Cancers Symposium", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Katou, Hirotoshi"}], "nameIdentifiers": [{"nameIdentifier": "670612", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "670613", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuda, Shigeo"}], "nameIdentifiers": [{"nameIdentifier": "670614", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Maeda, Yukiteru"}], "nameIdentifiers": [{"nameIdentifier": "670615", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "670616", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizoe, Junetsu"}], "nameIdentifiers": [{"nameIdentifier": "670617", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ootou, Masao"}], "nameIdentifiers": [{"nameIdentifier": "670618", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsujii, Hirohiko"}], "nameIdentifiers": [{"nameIdentifier": "670619", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "加藤 博敏", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670620", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山田 滋", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670621", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "安田 茂雄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670622", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "前田 幸輝", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670623", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鎌田 正", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670624", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "溝江 純悦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670625", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "大藤 正雄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670626", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻井 博彦", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "670627", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/68309", "pubdate": {"attribute_name": "公開日", "attribute_value": "2006-01-30"}, "publish_date": "2006-01-30", "publish_status": "0", "recid": "68309", "relation": {}, "relation_version_is_last": true, "title": ["Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial"], "weko_shared_id": -1}
Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial
https://repo.qst.go.jp/records/68309
https://repo.qst.go.jp/records/683092f174f1c-efa0-4ec7-97e2-81c1af9fb54b
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2006-01-30 | |||||
タイトル | ||||||
タイトル | Two-fraction carbon ion radiotherapy for hepatocellular carcinoma: Preliminary results of a phase I/II clinical trial | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Katou, Hirotoshi
× Katou, Hirotoshi× Yamada, Shigeru× Yasuda, Shigeo× Maeda, Yukiteru× Kamada, Tadashi× Mizoe, Junetsu× Ootou, Masao× Tsujii, Hirohiko× 加藤 博敏× 山田 滋× 安田 茂雄× 前田 幸輝× 鎌田 正× 溝江 純悦× 大藤 正雄× 辻井 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Introduction: We reported that the 4-fraction/1-week carbon ion radiotherapy (CIRT) appeared to be safe and to have a promising potential as a new, radical, and minimally invasive therapeutic option for hepatocellular carcinoma (HCC) at the 2004 ASCO annual meeting. In order to evaluate the safety and efficacy of 2-fraction/2-day CIRT, the next clinical trial was conducted within a phase I/II study between April 2003 and August 2005. Methods: The subjects of this report were 32 patients with follow-up period of over 6 months. CIRT was administered in doses of 32.0 to 38.8 cobalt gray equivalent (GyE) in 2 fractions for 2 days in a step-wise dose-escalation study. The median age was 68 (53-80) years. All patients had chronic liver diseases of Child-Pugh grade A in 30 or B in 2. Nine patients had intrahepatic recurrent lesions. The median tumor size was 4.7 (2.0-6.0) cm in diameter. Because no evaluation criteria are available for general hepatic toxicity in the impaired liver, the General Hepatic Toxicity Criteria based on NCI-CTC was defined by the Liver Cancer Working Group. Results: During a median follow-up of 18 (6-28) months, no treatment-related death occurred. Grade 3 hepatic toxicity according to NCI-CTC was observed in one patient in serum-GOT, GPT, T.BIL, and prothrombin activity. Grade 3 general hepatic toxicity occurred in the same one. No other Grade 3 or worse adverse events have occurred. The overall tumor response rate was 91% (29/32) at 6 months after the therapy. One-year and 1.5-year local control rate was 96% (23/24) and 88% (15/17), respectively. One-year and 1.5-year overall survival rate was 100% (24/24) and 94% (17/18), respectively. There were preliminarily no differences in results between the 2-fraction and 4-fraction CIRT. Conclusion: Two-fraction CIRT for HCC appears preliminarily safe and effective as well as the 4-fraction one. However, further observation is needed because the follow-up period is too short to confirm its clinical efficacy. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | 2006 Gastrointestinal Cancers Symposium | |||||
発表年月日 | ||||||
日付 | 2006-01-28 | |||||
日付タイプ | Issued |